Participants - All
Participant search result
Deputy Director of KIAT Europe
Deputy Director of KIAT Europe
Researcher (Eurostars NPC)
Seoul, South Korea
AT-31 BIO Inc. has developed GJK-012, a patent-pending immunosuppressant for use in innovative eye drops for Sjögren's syndrome dry eye disease. We seek investors, R&D co-developers, and Big Pharma M&A/licensing partners to advance clinical trials.
AT-31 BIO Inc. has developed GJK-012, a patent-pending immunosuppressant for use in innovative eye drops for Sjögren's syndrome dry eye disease. We seek investors, R&D co-developers, and Big Pharma M&A/licensing partners to advance clinical trials.
Leading the paradigm shift in immunology. AT-31 BIO delivers breakthrough solutions for complex immune disorders through advanced next-generation immunosuppressive therapies.
Leading the paradigm shift in immunology. AT-31 BIO delivers breakthrough solutions for complex immune disorders through advanced next-generation immunosuppressive therapies.
EUREKA Deputy HLR/ Director for International R&D Corperation
Seoul, South Korea